Investment Thesis
BioCryst exhibits strong revenue growth (94% YoY) indicating successful product commercialization, but faces critical solvency issues with negative stockholders' equity of -$553.8M and massive operating losses exceeding revenue. The company is burning cash operationally while carrying $395.2M in debt, creating an unsustainable capital structure that threatens long-term viability.
Strengths
- Exceptional revenue growth of 94% YoY to $156.4M demonstrates strong product market acceptance and commercial traction
- Adequate near-term liquidity with current ratio of 1.91x and $171.6M cash on hand
- Insider activity with 8 Form 4 filings in last 90 days suggests management confidence
Risks
- Negative stockholders' equity of -$553.8M indicates liabilities exceed total assets - critical solvency concern
- Massive operating losses of -$701.6M with operating margin of -448.6% and ongoing cash burn of -$62.2M FCF
- High debt load of $395.2M with negative interest coverage ratio of -14.2x - unable to service debt from operations
Key Metrics to Watch
- Path to operating cash flow breakeven and timeline to profitability
- Evolution of operating expenses and gross margins as revenue scales
- Debt covenant compliance, refinancing needs, and equity dilution plans
Financial Metrics
Revenue
156.4M
Net Income
-721.8M
EPS (Diluted)
$-2.98
Free Cash Flow
-62.2M
Total Assets
465.1M
Cash
171.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-448.6%
Net Margin
-461.5%
ROE
N/A
ROA
-155.2%
FCF Margin
-39.8%
Balance Sheet & Liquidity
Current Ratio
1.91x
Quick Ratio
1.88x
Debt/Equity
N/A
Debt/Assets
219.1%
Interest Coverage
-14.25x
Long-term Debt
395.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T09:18:47.876799 |
Data as of: 2026-03-31 |
Powered by Claude AI